Distribution Agreement


Medical Solutions PLC
11 February 2008

                                        For further information, please contact:

                                                           Medical Solutions plc
                                                                        Nick Ash
                                                               Managing Director
                                                              Tel: 0115 973 9010
                                                     www.medical-solutions.co.uk

                                                  Bishopsgate Communications Ltd
                                                          Nick Rome/Gemma O'Hara
                                                              Tel: 0207 562 3350
                                               www.bishopsgatecommunications.com



                                                                                   
                                                                11 February 2008


                             Medical Solutions plc
                     ("Medical Solutions" or the "Company")



                        EXCLUSIVE DISTRIBUTION AGREEMENT

Medical Solutions enters an exclusive UK agreement with Empire Genomics, LLC as
a distributor and service provider for ACCUArray genotyping


The Board of Medical Solutions plc (LSE: MLS), the provider of expert, quality
DNA sequencing and genotyping services to the healthcare, pharma biotech and
life sciences research sectors, is pleased to announce that it will partner with
Empire Genomics, Inc. to be the exclusive UK distributor and service provider
for its ACCUArray array comparative genomic hybridization ("aCGH") genotyping
technology.


In addition to distributing the product, Medical Solutions will also offer the
genotyping service from its laboratories in Nottingham, which will include
in-house bioinformatics analysis and support.


HIGHLIGHTS


  * Exclusive distributor and service provider in the UK;

  * Medical Solutions to offer both Human and Mouse ACCUArray aCGH as a
    product and also provide the genotyping service that will include in-house
    bioinformatic analysis;

  * Novel DNA array for pre-natal, cancer and pharmacogenetic testing with
    diagnostic and research applications;

  * Enhanced portfolio of genomic products and services provided in GLP, GCP
    and CPA accredited laboratories.


The addition of Empire Genomics ACCUArray will complement Medical Solutions
existing portfolio of genomic products and contract research services including
DNA clones and genomic analyses.  The assay has clinical diagnostic applications
for the healthcare community and can be used for pharmacogenetic testing by
companies in the pharma biotech sector.  This further demonstrates the Company's
commitment to be a market leader in the UK for the provision of expert, quality
laboratory services and genomic reagents to the healthcare and life science
research sectors.


Dr Tom Weaver, Commercial Director for Medical Solutions, said "The diagnostic
capability of this assay is of particular interest to those groups in the
healthcare community involved in cytogenetic and pre and post natal testing.
ACCUArray aCGH provides a tremendous tool for the identification of genetic
aberrations linked with a number of diseases and conditions such as cancer,
autism, mental health problems including Alzheimer's, several congenital
abnormalities and certain syndromes including Down Syndrome".


Dr Weaver added "The Empire Genomics aCGH kit, provides a high resolution and
robust screening procedure for researchers, clinicians and pharmacologists.  The
supporting software provides data analysis within 24 hours in a concise and
accessible format."




                                    - ends -



About Medical Solutions

Medical Solutions is a leading provider of expert, quality services and products
to the healthcare, pharma biotech and life science research sectors.  Its
Healthcare operations provide screening products and reference laboratory
diagnostic testing services for cancer and other diseases and additional
predictive testing for treatment optimisation for clinicians and patients.
Pharma Biotech Services offers support for early stage therapeutic development,
offering a "one-stop shop" from tissue pathology, immunohistochemistry,
sophisticated image analysis, biomarker determination and assay development to
pharmacogenomics including genotyping and gene expression analysis.  The Life
Science Research services provide core laboratory research support from
conceptualization to implementation, calling upon a wide ranging of cutting-edge
technology platforms including and an online catalogue of biomolecular tools.
This incorporates DNA sequencing, whole genome amplification and a comprehensive
library of genomic reagents and clones including cDNA and RNAi.

The group has its headquarters in Nottingham, UK where it operates state of the
art reference laboratory facilities, with additional UK laboratory facilities in
Cambridge and Oxford.   Medical Solutions is CPA, GLP and GCP accredited and is
licensed by the Human Tissue Authority.  Further information is available from
www.medical-solutions.co.uk


About Empire Genomics

Empire Genomics, based in Buffalo, New York, utilises proprietary techniques to
identify and quantify chromosomal abnormalities.  Specifically the company has
evolved array-based Comparative Genomic Hybridization ("aCGH") by developing
microarrays that utilize discrete segments of DNA generated from the Roswell
Park Cancer Institute ("RPCI") bacterial artificial chromosome ("BAC") clones.
These are of considerable diagnostic value to early stage disease detection and
treatment, and streamline the process by eliminating the need to grow cells or
obtain large sample amounts.  The company was founded on the research experience
of Dr Norma Nowak and her more than 100 peer reviewed research publications.
More information on Empire Genomics is available at www.empiregenomics.com.





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

NRAEASAPEDKPEFE
Medical Solutions (LSE:MLS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024